Global,Demand,for,Non,Small,Ce health Global Demand for Non Small Cell Lung Cancer Therapeutics Ma
If the vagina is not offering the firm grip to your male partner, he expresses displeasure in lovemaking. You need to tighten the orifice and regain lost elasticity. You can make use of herbal remedies for loose vagina treatment naturally. H The technology behind listening devices has improved dramatically in recent years, giving new hope to those with impairment. While still far from a perfect replacement for the natural ability to hear, these devices give those with a disabili
Transparency Market Research has published a new market report titled, “Non Small Cell Lung Cancer Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023.” According to the report, the global non small cell lung cancer market was valued at US$ 4.9 Bn in 2014 and is anticipated to expand at a CAGR of 12.1% from 2015 to 2023 to reach US$ 15.1 Bn in 2023. The report provides detailed analysis of current and emerging drugs for non small cell lung cancer (NSCLC), segmenting them based on type of drug class. Drugs have been analyzed by segments such as angiogenesis inhibitor, EGFR inhibitor, kinase inhibitor, microtubule stabilizer, folate antimetabolites, and PD-1/PD-L1 inhibitor. Angiogenesis inhibitor was the largest segment of the global non-small cell lung cancer market in 2014. High demand for Avastin in major geographies such as Europe and the U.S. is likely to propel the segment during the forecast period. The angiogenesis inhibitor segment was valued at US$ 1,627.1 Mn in 2014 and is likely to account for US$ 2,020.4 Mn by 2023, expanding at a CAGR of 1.8% from 2015 to 2023. The folate antimetabolites segment is projected to be the second highest segment of the global NSCLC therapeutics market. The EGFR inhibitor and microtubule stabilizer segments held the third and fourth largest shares of the market in terms of revenue in 2014. However, entry of new targeted therapies with more surveillance rate could restrain market growth. PD-1/PD-L1 inhibitor is likely to the fastest growing segment during the forecast period, due to affectivity of the treatment as clinical data showed double survival rate. The non-small cell lung cancer therapeutics market is anticipated to be driven by increase in incidence and diagnosis rate, government initiatives leading to rapid approval of the treatment, and development of targeted therapies Get a Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=504 The report offers a detailed analysis of factors responsible for market growth and outlines a possible growth trajectory for other segments. The report is thus compiled with the primary objective of updating the stakeholders with the market dynamics, which are graphically illustrated.AstraZeneca plc, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene Corporation, Novartis AG, Eli Lilly and Company, Pfizer, Inc., Genentech, Inc. (a Roche company), and Sun Pharmaceutical Industries Ltd. are the major companies operating in the global non small cell lung cancer therapeutics market. Genentech, a Roche company, was identified as the leading player in the global non-small cell lung cancer therapeutics market in 2014, accounting for a revenue share of more than 36%, followed by Eli Lilly and Company. The global non-small cell lung cancer therapeutics market has been segmented as follows:Global Non-Small Cell Lung Cancer Therapeutics Market, by Drug Class, 2013–2023 (US$ Mn)OverviewAngiogenesis InhibitorAvastin (bevacizumab)Cyramza (Ramucirumab)Epidermal Growth Factor Receptor BlockerTarceva (erlotinib)Gilotrif (afatinib)Iressa (gefitinib)Kinase InhibitorXalkori (crizotinib)Zykadia (ceritinib)Microtubule StabilizerAbraxane (paclitaxel protein bound)DocetaxelFolate AntimetabolitesAlimta (pemetrexed)PD-1/ PD-L1 InhibitorOpdivo (nivolumab)Keytruda (pembrolizumab)Pipeline Analysis: Global Non-Small Cell Lung Cancer Therapeutics MarketOverviewLate Stage (Phase III) Forecast for Phase III Drugs Post Expected Launch till 2023 (US$ Mn)Avelumab - Pfizer, Inc.MPDL3280A - RocheMEDI4736 - AstraZenecaAbemaciclib - Eli Lilly and CompanyOthersEarly Stage (Phase I and II) (Qualitative Analysis - Tabular representation)Global Non-Small Cell Lung Cancer Therapeutics Market, by Geography, 2013–2023 (US$ Mn)OverviewNorth AmericaU.S.CanadaEuropeU.K.GermanyRest of EuropeAsia PacificJapanChinaRest of Asia PacificRest of the World Contact us: Mr. Sudip STransparency Market Research90 State Street,Suite 700,AlbanyNY - 12207United StatesTel: +1-518-618-1030USA - Canada Toll Free 866-552-3453Email: [email protected]: http://www.transparencymarketresearch.com/
Global,Demand,for,Non,Small,Ce